Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription 09.03.2026 1 Anticancer Res 1 BMC Cancer 1 Cancer 1 Cancer Lett 1 Clin Cancer Res 1 Eur J Cancer 1 J Clin Invest 1 J Clin Oncol 1 J Nucl Med 1 Lung Cancer 1 Oncogene

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Anticancer Res

1. SATOH H, Miyazaki K, Nakamura R, Watanabe A, et al
   Leptomeningeal Metastasis in Patients With EGFR-positive NSCLC: A Propensity-matched Retrospective Study of Patients With EGFR-negative NSCLC.
   Anticancer Res. 2026;46:1685-1695.
   PubMed         Abstract available
   
   

   
   BMC Cancer

2. LI Y, Sun Z, Duan H, Song M, et al
   (125)Iodine brachytherapy stents for lung cancer with superior vena cava syndrome.
   BMC Cancer. 2026 Mar 4. doi: 10.1186/s12885-026-15777.
   PubMed        
   
   

   
   Cancer

3. PURI S, Elliott A, Naqash AR, Shukair HA, et al
   Multiomic characterization of small cell lung cancer: Real-world insights into therapeutic opportunities.
   Cancer. 2026;132:e70284.
   PubMed         Abstract available
   
   

   
   Cancer Lett

4. APPADURAI MI, Alsafwani ZW, Chaudhary S, Shah A, et al
   Ixazomib triggers autophagic degradation of MUC5AC/integrin-beta4 and inhibits non-small cell lung cancer progression.
   Cancer Lett. 2026 Feb 28:218333. doi: 10.1016/j.canlet.2026.218333.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

5. IRAJIZAD E, Fahrmann JF, Wu R, Rudsari H, et al
   Association of blood levels of forever plastics with lung cancer mortality among ever smokers in the Prostate Lung Colorectal and Ovarian (PLCO) cohort study.
   Clin Cancer Res. 2026 Mar 4. doi: 10.1158/1078-0432.CCR-25-3846.
   PubMed         Abstract available
   
   

   
   Eur J Cancer

6. EBERHARDT WEE, Schulte C, Pottgen C, Gauler TC, et al
   Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis.
   Eur J Cancer. 2026;236:116256.
   PubMed         Abstract available
   
   

   
   J Clin Invest

7. ZHUANG WT, Pang LL, Hu LY, Liao J, et al
   EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-gamma.
   J Clin Invest. 2026;136:e194377.
   PubMed         Abstract available
   
   

   
   J Clin Oncol

8. ZHOU H, Zhao H, Hou X, Wang Y, et al
   Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study.
   J Clin Oncol. 2026 Mar 4:JCO2501929. doi: 10.1200/JCO-25-01929.
   PubMed         Abstract available
   
   

   
   J Nucl Med

9. MA C, Cao M, Li L, Wu Q, et al
   CD70-Targeted [(18)F]RCCB6 Immuno-PET/CT for Diagnosing Clear Cell Renal Cell Carcinoma Metastases: A Prospective Study.
   J Nucl Med. 2025 Dec 11:jnumed.125.270958. doi: 10.2967/jnumed.125.270958.
   PubMed         Abstract available
   
   

   
   Lung Cancer

10. AIBA T, Hara S, Tominaga S, Yamamoto R, et al
    Real-world comparative effectiveness of atezolizumab versus durvalumab for extensive-stage small-cell lung cancer.
    Lung Cancer. 2026;214:109355.
    PubMed         Abstract available
    
    

    
    Oncogene

11. LIU Y, Chang Y, Li H, Wang J, et al
    CRTAC1 inhibits progression of lung adenocarcinoma by suppressing integrin/FAK signaling.
    Oncogene. 2026;45:946-960.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum